Yixintang Pharmaceutical Group Co., Ltd.

SZSE:002727 Stock Report

Market Cap: CN¥8.2b

Yixintang Pharmaceutical Group Balance Sheet Health

Financial Health criteria checks 6/6

Yixintang Pharmaceutical Group has a total shareholder equity of CN¥7.9B and total debt of CN¥495.5M, which brings its debt-to-equity ratio to 6.3%. Its total assets and total liabilities are CN¥17.1B and CN¥9.3B respectively. Yixintang Pharmaceutical Group's EBIT is CN¥507.1M making its interest coverage ratio 6.2. It has cash and short-term investments of CN¥3.2B.

Key information

6.3%

Debt to equity ratio

CN¥495.53m

Debt

Interest coverage ratio6.2x
CashCN¥3.24b
EquityCN¥7.87b
Total liabilitiesCN¥9.26b
Total assetsCN¥17.13b

Recent financial health updates

These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Jul 15
These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Recent updates

Calculating The Fair Value Of Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Dec 12
Calculating The Fair Value Of Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Yixintang Pharmaceutical Group (SZSE:002727) Might Be Having Difficulty Using Its Capital Effectively

Nov 22
Yixintang Pharmaceutical Group (SZSE:002727) Might Be Having Difficulty Using Its Capital Effectively

Yixintang Pharmaceutical Group's (SZSE:002727) Soft Earnings Are Actually Better Than They Appear

Nov 06
Yixintang Pharmaceutical Group's (SZSE:002727) Soft Earnings Are Actually Better Than They Appear

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

Sep 25
Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Jul 15
These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Jun 29
Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Jun 13
Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Jun 13
Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

May 27
Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

May 03
Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Apr 15
Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Mar 06
Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Financial Position Analysis

Short Term Liabilities: 002727's short term assets (CN¥9.9B) exceed its short term liabilities (CN¥7.6B).

Long Term Liabilities: 002727's short term assets (CN¥9.9B) exceed its long term liabilities (CN¥1.6B).

Debt to Equity History and Analysis

Debt Level: 002727 has more cash than its total debt.

Reducing Debt: 002727's debt to equity ratio has reduced from 19.9% to 6.3% over the past 5 years.

Debt Coverage: 002727's debt is well covered by operating cash flow (406.7%).

Interest Coverage: 002727's interest payments on its debt are well covered by EBIT (6.2x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 06:00
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yixintang Pharmaceutical Group Co., Ltd. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Haigang ChenChina International Capital Corporation Limited
Feifei XuChina Merchants Securities Co. Ltd.
Bing ZhaoChina Renaissance Securities